Next Treatments
Back to Eczema

ucenprubart

TypeInjection StageStopped · Phase 2 Why it stoppedDidn't work well enough · Eli Lilly and Company · Mar 14, 2025“The decision to terminate the study was due to efficacy/effectiveness reasons.” (NCT05911841) Latest updateDec 2, 2025Phase 2 results posted · Trial stopped early

What stands out

New approach in eczema

  • Binds to CD200 receptor, a receptor that helps limit inflammatory signals
  • Injection every 2 or 4 weeks in trials
Derived from FDA substance registry · NCT05911841 · UniProt Q8TD46 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT05911841
Stopped earlyThe decision to terminate the study was due to efficacy/effectiveness reasons.From the trial’s registry record
NCT05911841 · Ages 18–70 · This is a summary of trial data for informational purposes only. It is not medical advice.

History

Earliest recorded event: Nov 29, 2018. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Dec 2, 2025Phase 2 results posted · Trial stopped earlyA Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Why it stopped: The decision to terminate the study was due to efficacy/effectiveness reasons. ClinicalTrials.gov NCT05911841
  • Mar 14, 2025Trial stopped earlyReason: The decision to terminate the study was due to efficacy/effectiveness reasons. ClinicalTrials.gov NCT05911841
  • Oct 10, 2024Phase 2 main data collected · Trial stopped earlyA Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Why it stopped: The decision to terminate the study was due to efficacy/effectiveness reasons. ClinicalTrials.gov NCT05911841
  • Sep 7, 2021Phase 1 trial completedA Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis ClinicalTrials.gov NCT03750643
  • Nov 29, 2018Phase 1 trial startedA Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis ClinicalTrials.gov NCT03750643

Sources

Trials